Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Guizhounli Pharmaceutical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was ¥178 Mil.
Guizhounli Pharmaceutical Co's average Total Assets over the quarter that ended in Mar. 2026 was ¥2,829 Mil. Therefore, Guizhounli Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2026 was 6.28%.
The historical rank and industry rank for Guizhounli Pharmaceutical Co's ROA % or its related term are showing as below:
SHSE:603439'
s ROA % Range Over the Past 10 Years
Min: 1.53 Med: 12.43 Max: 20.36
Current: 1.67
During the past 13 years, Guizhounli Pharmaceutical Co's highest ROA % was 20.36%. The lowest was 1.53%. And the median was 12.43%.
SHSE:603439's ROA % is ranked worse than 55.9% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs SHSE:603439: 1.67
Guizhounli Pharmaceutical Co (SHSE:603439) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Guizhounli Pharmaceutical Co ROA % Related Terms
Guizhounli Pharmaceutical Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhounli Pharmaceutical Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's ROA % distribution charts can be found below:
* The bar in red indicates where Guizhounli Pharmaceutical Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Guizhounli Pharmaceutical Co (SHSE:603439) has a ROA % of 6.28% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Guizhounli Pharmaceutical Co and its competitors. This is 49% below median its historical median of 12.43. Over the past decade, Guizhounli Pharmaceutical Co's ROA % has ranged from 1.53 to 20.36. According to the industry distribution chart, Guizhounli Pharmaceutical Co ranks #564 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 55.9%.
Is Guizhounli Pharmaceutical Co's ROA % too high?
Guizhounli Pharmaceutical Co's current ROA % of 6.28% is 49% below median its 10-year median of 12.43. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 20.36. The Drug Manufacturers industry median ROA % is 2.74. Guizhounli Pharmaceutical Co's value of 6.28% is 129.2% above this industry median. Based on the distribution chart, Guizhounli Pharmaceutical Co ranks #564 out of 1009 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhounli Pharmaceutical Co ranks #564 out of 1009 companies for ROA %. This places Guizhounli Pharmaceutical Co in the lower half of its industry. The industry median ROA % is 2.74. Guizhounli Pharmaceutical Co's value of 6.28% is 129.2% above this benchmark. Historically, Guizhounli Pharmaceutical Co's own ROA % has ranged from 1.53 to 20.36 over the past decade. While the company's 10-year median is 12.43 vs. the industry median of 2.74, Guizhounli Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current ROA % of 6.28% is 129.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current ROA % is 6.28%, which is 49% below median its own 10-year median of 12.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.41 — trading 22.4% below its estimated fair value. The current ROA % is 6.28%, which is 49% below median its 10-year median of 12.43 and 129.2% above the Drug Manufacturers industry median of 2.74. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current ROA % is 6.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥11.41 is trading 22.4% below its estimated GF Value™ of ¥14.70.
GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603439:
ROA %: 6.28% (49% below median its 10-year median of 12.43)
GF Value™: ¥14.70 vs. price of ¥11.41 (22.4% below fair value)
Industry Position: 129.2% above the Drug Manufacturers median (#564 of 1009)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score
Get the complete analysis for SHSE:603439
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
